Prospects for Improving Quality Evaluation of the Live Brucellosis Vaccine in Terms of Specific Activity

Prophylactic immunisation against brucellosis is part of the National Immunisation Schedule for Epidemic Settings. The immunisation is performed with a live vaccine—a lyophilized suspension of the Brucella abortus strain 19 BА in a stabilizing medium. The paper presents the results of quality evaluation of 9 batches of live brucellosis vaccine that were submitted to the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality of the Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation for assessment of the product’s compliance with the established specifications. The paper also presents the results of evaluation of the passport information provided by the manufacturer for these batches. There is no doubt about the need for objective quality evaluation of brucellosis vaccines as well as about the significance of its improvement.

The aim of study was to assess the prospects for improving quality evaluation of live brucellosis vaccines in terms of Specific activity (concentration of microbial cells, number of living microbial cells, number of cutaneous doses).

Materials and methods: specific activity (concentration of microbial cells and number of living microbial cells) was determined by visual and microbiological methods using the industrial reference standard of brucellosis vaccine OSO 42-28-396-2018, batch 6 and the bacterial suspension of the Brucella abortus strain 19 BА acquired from the joint stock company Scientific and Production Association “Microgen” in 2016. The number of cutaneous doses in the brusellosis vaccine was determined by the calculation method. Statistical processing of the results was performed using Microsoft Excel.

Results: there was a mismatch between the brucella concentration coefficient of 1.7×109 microbial cells/mL determined by comparison with the industrial reference standard of bacterial suspension turbidity, 10 IU and the actual concentration of microbial cells obtained in the study. According to preliminary results, the brucella concentration coefficient corresponding to the industrial reference standard of bacterial suspension turbidity, 10 IU can reach 3.0×109 microbial cells/mL.

Conclusions: the obtained results can serve as a basis for amending the data on the brucella concentration coefficient in the Passport and the Instructions for use of the industrial reference standard of bacterial suspension turbidity, 10 IU, as well as the Specific activity section (concentration of microbial cells, number of living microbial cells, number of cutaneous doses) of the established specifications for the brucellosis vaccine. Before amending the information on the brucella concentration corresponding to 10 IU in the Passport and the Instructions for use of the reference standard of bacterial suspension turbidity (OSO 42-28-85P), additional studies should be performed with other types of brucella.

1. Zheludkov MM, Tsirelson LE. Reservoirs of Brucella infection in nature. Zoologicheskiy zhurnal = Zoological Journal. 2010;89(1):53–60 (In Russ.)

2. Lyamkin GI, Ponomarenko DG, Khudoleev AA, Vilinskaya SV, Zaytsev AA, Kulichenko AN. The epidemiological situation of brucellosis the Russian Federation and the member states of the Commonwealth of Independent States. Infektsionnyye bolezni. Novosti. Mneniya. Obucheniye = Infectious diseases: News, Opinions, Training. 2016;(1):68–74 (In Russ.)]

3. Okhapkina VYu, Pyatkova NV, Pavlov DL, Susloparov AA. Epidemic risk of brucellosis in modern conditions. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention. 2016;15(3):15–22 (In Russ.)

4. Popova TG, Novitskiy AA, Kolychev NM. Epizootological and environmental aspects of specific prophylaxis brucellosis. Veterinariya = Veterinary Medicine. 2012;(3):24–6 (In Russ.)

5. Tsirel'son LE, Zheludkov MM, Kulakov YuK. Overview of problems of vaccinal prevention of brucellosis. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention. 2013;3(70):77–81 (In Russ.)

6. Movsesyants AA, Mironov AN, Merkulov VA, Borisevich IV. Aims and objectives Testing Center for Quality Expertise of Medical Immunobiological Preparations. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2012;(1):7–9 (In Russ.)

7. Movsesyants AA, Bondarev VP, Olefir YV, Merkulov VA, Shimchuk LF. Quality standards for immunobiological medicinal products – new texts in the State Pharmacopoeia of the Russian Federation. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2016;(2):38–41 (In Russ.)

8. Fadeikina OV, Kasina IV, Alekseeva SA, Kovtun VP, Burdina EN, Ermolaeva TN, et al. Application of an industry standard sample of turbidity of bacterial suspensions to determine the total concentration of microbial cells in suspensions of anthrax, plague and brucellosis microbes. Uspekhi sovremennogo yestestvoznaniya = The successes of modern science. 2015;1(8):1287–90 (In Russ.)